Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial.

Front Immunol · 2026 · PMC13283993 · PMID 42338591

Europe PMC DOI

hedged sentence

0.2180

closest p · 4.4× alpha

0.2180

boldest claim

The sentences

did not reach statistical significanceP = 0.218not close (p > 0.1)

However, this observed change did not reach statistical significance (P = 0.218).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.